Top in endocrinology: Hypogonadism drug, SGLT2 inhibitors
Click Here to Manage Email Alerts
The FDA will review an oral testosterone undecanoate softgel manufactured by Marius Pharmaceuticals as a potential treatment for hypogonadism in men. The announcement was the top story in endocrinology last week.
Another top story was about a study investigating the benefits of SGLT2 inhibitors in patients with type 2 diabetes. Researchers looked at prescribing trends and found no significant link between improvements in glycemic control and the availability of the drugs.
Read these and more top stories in endocrinology below:
FDA accepts NDA for oral testosterone softgel for male hypogonadism
The FDA accepted a new drug application for an oral testosterone undecanoate softgel for the treatment of primary and secondary hypogonadism in men, according to a press release from the manufacturer. Read more.
SGLT2 inhibitors not cost effective for glycemic management alone in type 2 diabetes
SGLT2 inhibitors provide limited glycemic management benefits and may not be cost effective for most people with type 2 diabetes, according to a study published in the Journal of Diabetes and Its Complications. Read more.
BLOG: Daylight saving time and insulin pump clocks
As we “spring forward,” Saleh Aldasouqi, MD, FACE, ECNU, reminds people with diabetes who use insulin pumps to remember to adjust the time setting on their pump clocks. Read more.
Immunotherapy improves beta-cell function, delays type 1 diabetes diagnosis
A single 14-day course of the monoclonal antibody teplizumab had lasting effects on delay of type 1 diabetes diagnosis and improved beta-cell function for high-risk individuals, according to new data. Read more.
Thyroid disease does not influence COVID-19 progression
The risk for testing positive for COVID-19 or developing more severe disease does not differ between adults treated for hypothyroidism or hyperthyroidism and euthyroid controls, according to a Danish database analysis. Read more.